Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic…
History, Drug interactions & Pharmacology
Explore the main themes, entities and connections around Repaglinide. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
patent drug novo drugs hypoglycemia nordisk prandin action new blood cells insulin mechanism medication bioavailability may type diabetes antidiabetic japan
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Repaglinide | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Repaglinide | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Repaglinide | ATC code | A10BX02 (WHO) | 1.00 | infobox |
| Repaglinide | Bioavailability | 56% (oral) | 1.00 | infobox |
| Repaglinide | CAS Number | 135062-02-1 Y | 1.00 | infobox |
| Repaglinide | ChEMBL | ChEMBL1272 Y | 1.00 | infobox |
| Repaglinide | ChemSpider | 59377 Y | 1.00 | infobox |
| Repaglinide | CompTox Dashboard (EPA) | DTXSID3023552 | 1.00 | infobox |
| Repaglinide | DrugBank | DB00912 Y | 1.00 | infobox |
| Repaglinide | ECHA InfoCard | 100.158.190 | 1.00 | infobox |
| Repaglinide | Elimination half-life | 1 hour | 1.00 | infobox |
| Repaglinide | Excretion | Fecal (90%) and kidney (8%) | 1.00 | infobox |
| Repaglinide | Formula | C27H36N2O4 | 1.00 | infobox |
| Repaglinide | IUPHAR/BPS | 6841 | 1.00 | infobox |
| Repaglinide | KEGG | D00594 Y | 1.00 | infobox |
| Repaglinide | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Repaglinide | Legal status | CA: ℞-only | 1.00 | infobox |
| Repaglinide | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Repaglinide | Legal status | US: ℞-only | 1.00 | infobox |
| Repaglinide | Legal status | EU: Rx-only | 1.00 | infobox |
| Repaglinide | License data | EU EMA: by INN | 1.00 | infobox |
| Repaglinide | License data | US DailyMed: Repaglinide | 1.00 | infobox |
| Repaglinide | License data | US FDA: Prandin | 1.00 | infobox |
| Repaglinide | MedlinePlus | a600010 | 1.00 | infobox |
| Repaglinide | Melting point | 126 to 128 °C (259 to 262 °F) | 1.00 | infobox |
| Repaglinide | Metabolism | Liver oxidation and glucuronidation (CYP3A4-mediated) | 1.00 | infobox |
| Repaglinide | Molar mass | 452.595 g·mol−1 | 1.00 | infobox |
| Repaglinide | Pregnancy category | AU: C | 1.00 | infobox |
| Repaglinide | Protein binding | >98% | 1.00 | infobox |
| Repaglinide | PubChem CID | 65981 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.